Bayer/€BAYN
05:30
08:40
11:45
14:55
18:00
1D1W1MYTD1Y5YMAX
About Bayer
Bayer AG, operating under the ticker BAYN, is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863, the company is headquartered in Leverkusen, Germany, and operates in several sectors, including Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Bayer is known for developing new molecules for use in innovative products and solutions to improve the health of humans, animals, and plants.
Ticker
€BAYN
Sector
Primary listing
XETRA
Employees
89,556
Headquarters
Website
Bayer Metrics
BasicAdvanced
€29B
-
-€3.48
1.00
€0.11
0.38%
Price and volume
Market cap
€29B
Beta
1
52-week high
€29.88
52-week low
€18.38
Average daily volume
226K
Dividend rate
€0.11
Financial strength
Current ratio
1.133
Quick ratio
0.726
Long term debt to equity
103.954
Total debt to equity
125.99
Interest coverage (TTM)
3.66%
Profitability
EBITDA (TTM)
7,333
Gross margin (TTM)
56.39%
Net profit margin (TTM)
-7.40%
Operating margin (TTM)
10.91%
Effective tax rate (TTM)
0.47%
Revenue per employee (TTM)
€520,000
Management effectiveness
Return on assets (TTM)
2.80%
Return on equity (TTM)
-10.27%
Valuation
Price to revenue (TTM)
0.619
Price to book
0.94
Price to tangible book (TTM)
-1.59
Price to free cash flow (TTM)
6.22
Free cash flow yield (TTM)
16.08%
Free cash flow per share (TTM)
4.676
Dividend yield (TTM)
0.38%
Forward dividend yield
0.38%
Growth
Revenue change (TTM)
-1.99%
Earnings per share change (TTM)
169.77%
3-year revenue growth (CAGR)
-1.53%
10-year revenue growth (CAGR)
0.36%
3-year earnings per share growth (CAGR)
-6.92%
10-year earnings per share growth (CAGR)
-2.07%
3-year dividend per share growth (CAGR)
-61.97%
10-year dividend per share growth (CAGR)
-26.05%
What the Analysts think about Bayer
Analyst ratings (Buy, Hold, Sell) for Bayer stock.
Bulls say / Bears say
Bayer raised its 2025 currency-adjusted sales guidance by €1 billion at both ends to €46–48 billion and lifted adjusted EBITDA outlook to €9.7–10.2 billion following strong Q2 performance (Reuters)
Bayer’s Pharmaceuticals division saw combined first-quarter revenues of €680 million from new launch drugs Nubeqa and Kerendia, underscoring robust uptake of its growth portfolio (Reuters)
Bayer extended CEO Bill Anderson’s contract through March 2029, signalling supervisory board confidence in his turnaround strategy and ensuring leadership stability (Reuters)
Bayer added €1.2 billion to its U.S. Roundup litigation reserves, leaving approximately 61,000 unresolved claims and highlighting the ongoing legal overhang (Reuters)
Bayer announced significant cutbacks at its German Crop Science sites, ceasing herbicide production by 2028 amid intense price competition and regulatory pressures from low-cost Asian rivals (Reuters)
Bayer’s first-quarter net income fell over 35% year-on-year to €1.3 billion, driven by a near-tripling of litigation and restructuring charges to €587 million, underscoring persistent margin pressures (Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Bayer Financial Performance
Revenues and expenses
Bayer Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bayer stock?
Bayer (BAYN) has a market cap of €29B as of October 03, 2025.
What is the P/E ratio for Bayer stock?
The price to earnings (P/E) ratio for Bayer (BAYN) stock is 0 as of October 03, 2025.
Does Bayer stock pay dividends?
Yes, the Bayer (BAYN) stock pays dividends to shareholders. As of October 03, 2025, the dividend rate is €0.11 and the yield is 0.38%. Bayer has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Bayer dividend payment date?
The next Bayer (BAYN) dividend payment date is unconfirmed.
What is the beta indicator for Bayer?
Bayer (BAYN) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.